Nadia Harbeck

Apr 25, 2024 | nature.com | Matthew Goetz |Sara M. Tolaney |Valentina Guarneri |Miguel Cabral Martin |Miguel Martín |Nadia Harbeck | +1 more

AbstractIn monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively manage adverse events. Exploratory analyses to investigate the impact of dose reductions on efficacy were conducted.

Apr 14, 2024 | jhoponline.com | Hope Rugo |Sara M. Tolaney |Nadia Harbeck |Tajuana Bradley

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CGTajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CGTajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

Jan 22, 2024 | brnw.ch | Dennis J. Slamon |Hope Rugo |Nadia Harbeck

CLINICAL TRIAL UPDATES Background Since the initial development and approval of palbociclib, first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, for estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) on the basis of PALOMA-1 in 2015,1-4 the CDK4/6 inhibitor class has transformed the treatment landscape and, in combination with endocrine therapy (ET), has become the standard of care for the disease.5 PALOMA-2...

Jan 22, 2024 | ascopubs.org | Dennis J. Slamon |Hope Rugo |Nadia Harbeck

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

Dec 20, 2023 | jhoponline.com | Nadia Harbeck

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.